38 results about "Microangiopathy" patented technology

The invention provides a stem cell exosome vesicle induced by traditional Chinese medicine functional components as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method of the stem cell exosome vesicle, traditional Chinese medicine functional components serve as an exosome inducer, stem cells can be induced to proliferate and secrete exosome with the enhanced function, the yield of the exosome can be increased, bioactive molecules can be loaded, and the bioavailability of the exosome in diabetes treatment is remarkably improved. The stem cell exosome vesicle disclosed by the invention can be applied to treatment of diabetes and complications thereof, not only can improve functions of islet cells, but also can treat chronic inflammation, microangiopathy and other metabolic diseases related to diabetes, and has a wide clinical application prospect.

The present invention discloses the application of ginseng exosomes in the preparation of nanomedicines for treating diabetic ulcer vascular lesions, and relates to the field of biomedicine. The present invention verifies through experiments that ginseng exosomes can reprogram the glycolysis process of vascular endothelial cells under high sugar conditions, and inhibit the expression of acetyl coenzyme A in cells, reduce the production of reactive oxygen species, and then promote the expression of nitric oxide synthase, thereby reducing or reversing cell apoptosis induced by high sugar. Ginseng exosomes are used as nanomedicines to prevent, treat or improve diabetic ulcer microangiopathy. The ginseng exosomes in the present invention have a simple preparation process, low cytotoxicity, high delivery efficiency, and good stability. They can be used as a new type of nanomedicine for the prevention, treatment or improvement of diseases related to diabetic vascular lesions.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The invention discloses a cardiovascular and cerebrovascular disease information management method and system, and relates to the technical field of genomics, and the method comprises the steps: collecting health information and a biological sample of a patient, and generating a health file; performing genomics analysis by using the generated health archive, and calculating a genetic risk score of the patient; according to the genetic risk score of the patient, microvascular lesion detection is carried out on the high-risk patient, microvascular anomaly indexes are quantified, and an individualized health risk score is generated; metabonomics analysis is carried out based on the health risk score, and the metabolic state and metabolic capability of the patient are evaluated; combining the metabolism assessment result, the genetic risk score and the health risk score to formulate an individualized intervention scheme; the problems of data isolation and intervention generalization in the prior art are solved, and powerful technical support is provided for early prevention and accurate management of cardiovascular and cerebrovascular diseases.

The present invention relates to a double-stranded siRNA analogue for inhibiting expression of mannan-binding lectin-related serine protease 2 (MASP2), and a preparation method and use thereof, the double-stranded siRNA analogue can inhibit expression of MASP2, and is used for preventing and / or treating MASP2-related diseases and symptoms, such as MASP2-related diseases and disorders. The diseases and symptoms comprise IgA nephropathy, membranous nephropathy, lupus nephritis, thrombotic microangiopathy, systemic lupus erythematosus and the like.

The present invention encompasses the use of general chymotrypsin inhibitors, and more specifically, substituted bicyclic substituted uracil of general formula (I) as described and defined herein, and 3-methylbenzo-[b] thiophene)-2-sulfonamido derivatives of general formula (II) for the manufacture of pharmaceutical compositions for the treatment or prevention of stroke, pulmonary embolism, pulmonary embolism, and the like. The traditional Chinese medicine composition can be used for treating thrombosis, deep vein or superficial vein thrombosis, thrombotic microangiopathy, infection, inflammation, thrombotic microangiopathy in a hypercoagulable state after transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, and thrombosis or occlusion at a vascular access part.

The present application relates to adrenergic receptor ADRAC2 antagonists, to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The present application relates to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The invention relates to a traditional Chinese medicine composition for treating portal vein and hepatic sinus vascular diseases. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 13-17 parts of astragalus membranaceus, 13-17 parts of angelica sinensis and 4-8 parts of leech. The invention also provides application of the traditional Chinese medicine composition in preparation of medicines for treating portal vein and hepatic sinus vascular diseases. According to the invention, an SD (Sprague Dawley) rat is fed with selenium-rich diet, meanwhile, a model is made according to a chemotherapy regimen of FOLFOX intravenously injected into the tail of the rat every week, the model is made continuously for 8 weeks, a PSVD animal model is copied, the modified Chinese angelica blood replenishing decoction is fed for intervention while the model is made, and simvastatin is taken as a positive control. Results show that the modified Chinese angelica blood replenishing decoction can significantly reduce the portal vein pressure of rats and improve related expressions of liver microangiopathy. The liver index is obviously reduced, and the spleen index is improved. Liver tissue pathological reticular staining and Japanese stellate red staining show that both the liver tissue and the Japanese stellate red staining are relieved.

The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

The invention relates to the technical field of medical instruments, and discloses a diabetic microangiopathy auxiliary detection device which comprises a base, a stand column is arranged on the upper surface of the base, a bearing seat is arranged at the upper end of the stand column, a mounting seat is arranged on the bearing seat, a bundling assembly is arranged on the mounting seat, and the bundling assembly comprises a tourniquet. The tourniquet comprises an outer sheet body and a connecting plate, two fixed pulleys which are horizontally arranged are arranged on the mounting seat, the outer sheet body is made of an elastic metal sheet, the outer sheet body comprises a circular ring section and a vertical section, at the beginning, the circular ring section is located above the fixed pulleys, and the axis of the circular ring section is parallel to the axis of the fixed pulleys; a notch is formed in the lowest point of the outer circle face of the circular ring section, the two vertical sections are arranged at the two ends of the notch of the circular ring section respectively, the connecting positions of the vertical sections and the circular ring section are in an arc shape, the two fixed pulleys are located on the opposite sides of the two vertical sections respectively, the two fixed pulleys are tangent to the two connecting positions respectively, and an inner air bag is arranged on the inner wall of the outer sheet body.

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.

The present application relates to novel substituted heterocyclic carboxamides, methods of their preparation, their use alone or in combination for the treatment and / or prevention of diseases and their use for the manufacture of a medicament for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of respiratory distress, including sleep-induced respiratory distress, such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular disorders, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The present application relates to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The invention relates to a health product, in particular to application of a mulberry leaf extract in preparation of a product for treating diabetic complications. The diabetic complication is cerebrovascular lesion or abnormal cerebral blood flow perfusion; the product comprises a food or a pharmaceutical composition; the invention proves that the mulberry leaf extract has a promoting effect on cerebral microangiogenesis and cerebral blood perfusion of diabetic mice; the mulberry leaf extract promotes proliferation of vascular endothelial cells, activates angiogenesis, cell migration and glycolipid metabolism pathways in a diabetes model, and enhances the migration ability of the vascular endothelial cells and mitochondrial membrane potential; the mulberry leaf extract can be used for preventing and treating microangiopathy caused by diabetes mellitus and improving related diseases caused by abnormal cerebral blood perfusion, and has the effects of improving anxiety-like behaviors and cognitive functions of diabetic mice.

The present application relates to adrenergic receptor ADRAC2 antagonists, to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition for treating diabetic microangiopathy and a preparation method thereof, the pharmaceutical composition comprising the following raw materials in parts by weight: active drug 5-10 parts, shell copolymer 20 parts, PLGA 35-50 parts, emulsifier 1.5 parts and freeze-drying protective agent 4 parts. The shell copolymer prepared and synthesized from PCL, PEG and a targeting peptide has functions such as drug loading, self-assembly, responsiveness and targeting, the responsiveness of which depends on a disulfide bond connecting the PCL and the PEG, the disulfide bond is broken in an abnormal blood flow environment of a vascular lesion, various drugs in the nanoparticle core are released, and the drug delivery efficiency and the treatment effect are greatly improved.

The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

The application relates to the technical field of traditional Chinese medicines, and discloses application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating diabetic microangiopathy, wherein the traditional Chinese medicine composition can improve blood perfusion and blood oxygen content of the foot skin of a diseased rat, reduce whole blood viscosity, has a certain protective effect on eyeball retina injury of a diabetic vasculopathy rat, inhibits infiltration of inflammatory cells in kidney tissue of a diabetic microangiopathy rat, improves glomerular basement membrane morphology, improves edema of proximal tubular epithelial cells, has a certain protective effect on foot skin injury of a diabetic microangiopathy rat, and reduces ET-1 level and Cys-C level in serum.

The invention provides application of a blood coagulation four-item detection reagent, a plasma D dimer detection reagent and an AT-III detection reagent in preparation of a diabetic microangiopathy detection kit and the kit, and relates to the technical field of medical biology. The research finds that the microangiopathy of the T2DM patient is obviously associated with the four blood coagulation items, the plasma D dimer and the AT-III level, and the four blood coagulation items, the plasma D dimer and the AT-III all cause independent influence factors of the microangiopathy, so that the risk of the microangiopathy of the T2DM patient can be predicted by detecting related indexes clinically; the clinical auxiliary diagnosis value is relatively high; further, prothrombin time detection results, activated partial thromboplastin time detection results, thrombin time detection results and fibrinogen detection results can be obtained on the basis of a four-item blood coagulation detection reagent, a plasma D dimer detection reagent and an AT-III detection reagent; determining the risk of the diabetic microangiopathy according to at least one of a blood plasma D dimer detection result and an antithrombin III detection result.

The invention belongs to the technical field of biological pharmacy, and provides application of a sanguisorba officinalis extract and functional components thereof in treatment of microangiopathy, and the application is that the sanguisorba officinalis extract and a preparation thereof are applied to preparation of a medicine for treating microangiopathy. According to the invention, a diabetic coronary artery microvessel (diabetic CMVD) injury model is established through combination of STZ and high-fat feed induction, and the treatment effect of the prepared sanguisorba officinalis extract and the functional component ziyuglycoside II thereof on microangiopathy is evaluated; results show that the sanguisorba officinalis extract and the functional components thereof can achieve the purpose of treating microvessels by improving lipid metabolism and insulin secretion of diabetic CMVD mice, myocardial injury of the diabetic CMVD mice, chronic inflammation of the diabetic CMVD mice, kidney microvessel injury of the diabetic CMVD mice and heart microvessel injury of the diabetic CMVD mice.

The invention discloses an application of BEZ235 in preparation of a medicine for treating or improving retina microangiopathy. Experiments show that BEZ235 can inhibit proliferation and migration of retinal vascular endothelial cells, inhibit the tube forming ability of the retinal vascular endothelial cells, inhibit the formation of pathological new vessels under the condition of oxygen-induced retinopathy and the enlargement of a non-vascular perfusion area, and inhibit the proliferation and migration of the retinal vascular endothelial cells and the tube forming ability of the retinal vascular endothelial cells. The number of pre-retinal neovascularization cells under the condition of oxygen-induced retinopathy is reduced, and the structural disorder of the retina is improved. Therefore, BEZ235 is useful in the prevention and treatment of retinal microangiopathy.

The present invention concerns clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising von Willebrand factor protease. The present invention also concerns an ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount LC of clusterin, and 2) comparing the amount Lc measured in step 1) with an amount Lref of clusterin by calculating the score S1=LC / Lref, in which: •If S1≤1, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, •If S1>1, the patient is not considered to be likely to benefit from treatment of TMA with clusterin.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The invention discloses a biomarker for auxiliary diagnosis of SLE (systemic lupus erythematosus) and application of the biomarker, and belongs to the technical field of biology. The invention discloses one of an anti-NPM1 antibody, an anti-RPLP2 antibody and an anti-MX1 antibody or a combination of any two or three of the anti-NPM1 antibody, the anti-RPLP2 antibody and the anti-MX1 antibody, which can be used as a biomarker for auxiliary diagnosis of SLE. And the kit can be used for auxiliary monitoring of SLE disease activity and auxiliary diagnosis of SLE (combined anti-phospholipid antibody) with clinical phenotypes of arterial thrombosis, microangiopathy, heart valve enuresis and thrombocytopenia, and has good diagnosis efficiency.

The invention relates to ADAMTS13 protein variants comprising residues 1 to 685 of ADAMTS13 and wherein one or more N-linked glycosylation sites are added as compared to wild-type ADAMTS13 and / or one or more existing N-linked glycosylation sites are shifted as compared to wild-type ADAMTS13. The invention further relates to compositions comprising such ADAMTS13 variants, methods for their preparation and uses thereof, in particular as an antithrombotic agent, and in the treatment of thrombotic disease, thrombotic microangiopathy, thrombotic thrombocytopeniaurpura (TTP), hemolytic-uremic syndrome (HUS), ischemic stroke, systemic thrombosis, COVID19, antiphospholipid syndrome, pre-eclampsia / HELLP syndrome, sepsis and sickle cell disease.

The invention discloses a nuclear medicine imaging technology-based evaluation method for treating myocardial microvascular diseases by using mesenchymal stem cell exosomes, and relates to the technical field of cardiovascular disease diagnosis. The method comprises the following steps that 1, after a microsphere embolism method is used for modeling, 18F-Flurridaz microPET / CT is used for conducting resting state imaging and Regadenoson load state imaging, Pmod software is used for analysis to obtain myocardial coronary artery blood flow reserve (CFR) of a model mouse, and the myocardial microvessel blood perfusion injury degree is determined; 2, after sequential treatment is carried out through exosomes of the mesenchymal stem cells, a 18F-FDG tracer agent is regularly injected in an intravenous mode, microPET / CT scanning is carried out, and metabolism imaging data of the cardiac muscle of the model mouse is obtained; 3, after scanning, PMOD software is used for processing imaging data, a myocardial bullseye map is generated, the myocardial bullseye map can display metabolism conditions of all segments of the myocardium, and by comparing metabolism values before and after treatment, the metabolism improvement effect of treatment on all the segments of the myocardium is analyzed, and the influence of treatment on myocardial energy metabolism recovery is revealed.

In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

The application discloses a kind of IV collagen targeted calcium dobesilate enteric microsphere capsules and preparation method thereof, belong to the technical field of pharmaceutical preparation.The capsule takes calcium dobesilate as main drug, adopts chitosan-sodium alginate ion crosslinking microsphere as carrier, is modified by RGD base sequence small peptide of specific binding IV collagen, and is wrapped Eudragit L100 enteric coating layer, realizes the dual action of active targeting and passive targeting.The application solves the problems of weak targeting, poor gastric acid stability and low bioavailability of existing calcium dobesilate preparation, and the enrichment concentration of drug in retinal and renal microvascular lesion site is increased by more than 4 times, while the stability and dissolution uniformity of the preparation are significantly improved.The preparation process is simple, suitable for industrial mass production, and can be used for preparing drugs for treating diabetic retinopathy and diabetic nephropathy.

The present invention relates to a 2-indolinone compound serving as a VEGFR and PKa dual-target inhibitor, and a preparation method therefor and a use thereof. Specifically, the present invention relates to a 2-indolone compound represented by general formula (I), and a preparation method therefor and a use thereof, particularly used for treating or preventing microangiopathy-related diseases mediated by high levels of VEGF protein and PKa protein, such as diabetic macular edema (DME) and age-related macular degeneration (AMD).